Roche on COVID-19 healthcare and testing: the pharmaphorum podcastFor episode 30 I spoke with Dr Ashton Harper, who’s head of medical affairs in the UK and Share XRoche on COVID-19 healthcare and testing: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/roche-covid-health-testing/
Roche and PatchAi partner on digital tool for cancer patientsRoche’s Italian subsidiary has joined forces with digital health startup PatchAi to roll out an app that aims Share XRoche and PatchAi partner on digital tool for cancer patientshttps://pharmaphorum.com/news/roche-and-patchai-partner-on-digital-tool-for-cancer-patients/
Roche targets wet AMD with faricimab and its 16-week regimenTwin late-stage trials of Roche’s ophthalmology drug faricimab have hit the mark in “wet” age-related macular degeneration trial, Share XRoche targets wet AMD with faricimab and its 16-week regimenhttps://pharmaphorum.com/news/faricimab/
NICE rejects BMS’ Zeposia MS pill in provisional guidanceNICE has said that the NHS should not fund Bristol-Myers Squibb’s multiple sclerosis pill Zeposia (ozanimod) for relapsing Share XNICE rejects BMS’ Zeposia MS pill in provisional guidancehttps://pharmaphorum.com/market-access-2/nice-rejects-bms-zeposia-ms-pill-in-provisional-guidance/
Scotland backs Roche’s Rozlytrek for ROS1 lung cancerThe Scottish Medicines Consortium (SMC) has given a green light to Roche’s Rozlytrek for a rare form of Share XScotland backs Roche’s Rozlytrek for ROS1 lung cancerhttps://pharmaphorum.com/news/scotland-backs-roches-rozlytrek-for-ntrk-tumours/
RNAi biotech Atalanta debuts with $110m plus Biogen and Roche CNS tie-upsUS biotech Atalanta Therapeutics has come out of stealth mode backed with $110m from Biogen and Roche, who Share XRNAi biotech Atalanta debuts with $110m plus Biogen and Roche CNS tie-upshttps://pharmaphorum.com/news/rnai-biotech-atalanta-debuts-with-110m-plus-biogen-and-roche-cns-tie-ups/
IL-6 drugs do work in COVID-19, says UK, as it plans NHS useNew data means that IL-6 drugs from Roche and Sanofi that had been all-but written off as coronavirus Share XIL-6 drugs do work in COVID-19, says UK, as it plans NHS usehttps://pharmaphorum.com/news/il-6-drugs-covid-19-new-trial/
Roche nabs breakthrough tag for TIGIT cancer immunotherapyRoche’s closely-watched combination of two checkpoint inhibitors – TIGIT-targeting tiragolumab and PD-L1 drug Tecentriq – has claimed breakthrough Share XRoche nabs breakthrough tag for TIGIT cancer immunotherapyhttps://pharmaphorum.com/news/roche-nabs-breakthrough-tag-for-tigit-cancer-immunotherapy/
Roche set to file ophthalmology drug faricimab in DMERoche looks set to mount a challenge to Bayer’s ophthalmology drug Eylea in 2021 after its faricimab antibody Share XRoche set to file ophthalmology drug faricimab in DMEhttps://pharmaphorum.com/news/roche-set-to-file-ophthalmology-drug-faricimab-in-dme/
